The MIT Center for Biomedical Innovation (CBI) announces a collaboration with the Amgen...
A recently published market report indicates that the use of robots in a number of industries...
The March issue of Pharmaceutical Processing is our INTERPHEX 2014 show issue and features numerous highlights from show exhibitors. In addition, we also announce the winners in our new Facility Excellence Awards program.
The Caliber Biotherapeutics manufacturing facility in Bryan, Texas offers an interesting look at the development and integration of Plant Made Pharmaceuticals. This commitment to new and innovative drug development strategies has led to it being recognized as one of Pharmaceutical Processing’s Facility Excellence Award winners for 2014.
New development technologies, expanded contract manufacturing and service capabilities, as well as innovative equipment investment strategies highlight leading practices from the best in pharmaceutical processing comprise the 2014 Pharmaceutical Processing Facility Excellence Award winners.
GW Pharmaceuticals plc today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Application Serial Number 13/606,742, a patent application directed to the spray device of its Sativex® product formulation.
This free white paper, 5 Must Have Strategies for Enterprise Quality, shows how quality can take a more prominent, enterprise-scale role.
A compelling read that at times is light hearted and funny, 7 Habits of Quality Obsessed Manufacturers is written for top performing quality professionals that want to give their company an edge.
An Executive Guide to Pharmaceutical Manufacturing Efficiency and the Effect of Environmental LegislationAugust 9, 2010 10:36 am | White Papers
This paper describes the use and waste of organic solvents in pharmaceutical manufacturing and the possible impact that greenhouse gas legislation, in the form of a carbon tax, may have on solvent usage and pharmaceutical manufacturing costs.
Recent studies covering plants in the U.S., UK and Germany show that controlling static electricity build-up is the key to preventing combustible cloud explosions.
This White Paper reviews the FDA’s Guidance addressing cardiovascular safety assessment during the development of new antidiabetic therapies for T2DM.